Abstract
Aims/hypothesis
An abnormal urinary albumin excretion rate (AER) is often the first clinically detectable manifestation of diabetic nephropathy. Our aim was to estimate the heritability and to detect genetic variation associated with elevated AER in patients with type 1 diabetes.
Methods
The discovery phase genome-wide association study (GWAS) included 1,925 patients with type 1 diabetes and with data on 24 h AER. AER was analysed as a continuous trait and the analysis was stratified by the use of antihypertensive medication. Signals with a p value <10−4 were followed up in 3,750 additional patients with type 1 diabetes from seven studies.
Results
The narrow-sense heritability, captured with our genotyping platform, was estimated to explain 27.3% of the total AER variability, and 37.6% after adjustment for covariates. In the discovery stage, five single nucleotide polymorphisms in the GLRA3 gene were strongly associated with albuminuria (p < 5 × 10−8). In the replication group, a nominally significant association (p = 0.035) was observed between albuminuria and rs1564939 in GLRA3, but this was in the opposite direction. Sequencing of the surrounding genetic region in 48 Finnish and 48 UK individuals supported the possibility that population-specific rare variants contribute to the synthetic association observed at the common variants in GLRA3. The strongest replication (p = 0.026) was obtained for rs2410601 between the PSD3 and SH2D4A genes. Pathway analysis highlighted natural killer cell mediated immunity processes.
Conclusions/interpretation
This study suggests novel pathways and molecular mechanisms for the pathogenesis of albuminuria in type 1 diabetes.
Similar content being viewed by others
Abbreviations
- AER:
-
Albumin excretion rate
- ACR:
-
Albumin-to-creatinine ratio
- AHT:
-
Antihypertensive
- CEU:
-
Centre d’Etude du Polymorphisme (Utah residents with northern and western European ancestry)
- ESRD:
-
End-stage renal disease
- FinnDiane:
-
Finnish Diabetic Nephropathy study
- GLRA3 :
-
Glycine receptor subunit α-3
- GWAS:
-
Genome-wide association study
- LD:
-
Linkage disequilibrium
- MAF:
-
Minor allele frequency
- NFS-ORPS:
-
UK Nephropathy Family Study and Oxford Regional Prospective Study
- nU-AER:
-
Overnight urine AER
- QQ-plot:
-
Quantile–quantile plot
- SDR:
-
Scania Diabetes Registry
- SNP:
-
Single nucleotide polymorphism
- SUMMIT:
-
SUrrogate markers for Micro- and Macro-vascular hard endpoints for Innovative diabetes Tools
- UK-ROI:
-
All Ireland-Warren 3-Genetics of Kidneys in Diabetes UK and Republic of Ireland
References
Nathan DM, Zinman B, Cleary PA et al (2009) Modern-day clinical course of type 1 diabetes mellitus after 30 years’ duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983–2005). Arch Intern Med 169:1307
Caramori ML, Fioretto P, Mauer M (2006) Enhancing the predictive value of urinary albumin for diabetic nephropathy. J Am Soc Nephrol 17:339–352
Remuzzi G, Benigni A, Remuzzi A (2006) Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 116:288–296
Groop PH, Thomas MC, Moran JL et al (2009) The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 58:1651
Tarnow L, Groop PH, Hadjadj S et al (2008) European rational approach for the genetics of diabetic complications–EURAGEDIC: patient populations and strategy. Nephrol Dial Transplant 23:161–168
Parving HH, Smidt UM (1986) Hypotensive therapy reduces microvascular albumin leakage in insulin-dependent diabetic patients with nephropathy. Diabet Med 3:312–315
Ritz E, Viberti GC, Ruilope LM et al (2010) Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. Diabetologia 53:49–57
Forsblom CM, Kanninen T, Lehtovirta M, Saloranta C, Groop LC (1999) Heritability of albumin excretion rate in families of patients with type II diabetes. Diabetologia 42:1359–1366
Krolewski AS, Poznik GD, Placha G et al (2006) A genome-wide linkage scan for genes controlling variation in urinary albumin excretion in type II diabetes. Kidney Int 69:129–136
Quinn M, Angelico MC, Warram JH, Krolewski AS (1996) Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia 39:940–945
Harjutsalo V, Katoh S, Sarti C, Tajima N, Tuomilehto J (2004) Population-based assessment of familial clustering of diabetic nephropathy in type 1 diabetes. Diabetes 53:2449–2454
Boger CA, Chen MH, Tin A et al (2011) CUBN is a gene locus for albuminuria. J Am Soc Nephrol 22:555–570
Fioretto P, Mauer M (2010) Diabetic nephropathy: diabetic nephropathy-challenges in pathologic classification. Nat Rev Nephrol 6:508–510
Sandholm N, Salem RM, McKnight AJ et al (2012) New susceptibility loci associated with kidney disease in type 1 diabetes. PLoS Genet 8:e1002921
Pezzolesi MG, Poznik GD, Mychaleckyj JC et al (2009) Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes. Diabetes 58:1403–1410
Thorn LM, Forsblom C, Fagerudd J et al (2005) Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care 28:2019–2024
Del Bo R, Scarlato M, Ghezzi S et al (2006) VEGF gene variability and type 1 diabetes: evidence for a protective role. Immunogenetics 58:107–112
Lindholm E, Agardh E, Tuomi T, Groop L, Agardh CD (2001) Classifying diabetes according to the new WHO clinical stages. Eur J Epidemiol 17:983–989
Mollsten A, Kockum I, Svensson M et al (2008) The effect of polymorphisms in the renin–angiotensin–aldosterone system on diabetic nephropathy risk. J Diabet Complicat 22:377–383
Amin R, Widmer B, Prevost AT et al (2008) Risk of microalbuminuria and progression to macroalbuminuria in a cohort with childhood onset type 1 diabetes: prospective observational study. BMJ 336:697–701
Marcovecchio ML, Dalton RN, Schwarze CP et al (2009) Ambulatory blood pressure measurements are related to albumin excretion and are predictive for risk of microalbuminuria in young people with type 1 diabetes. Diabetologia 52:1173–1181
McKnight AJ, Patterson CC, Pettigrew KA et al (2010) A GREM1 gene variant associates with diabetic nephropathy. J Am Soc Nephrol 21:773–781
Li Y, Willer C, Sanna S, Abecasis G (2009) Genotype imputation. Annu Rev Genomics Hum Genet 10:387–406
Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR (2010) MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet Epidemiol 34:816–834
Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D (2006) Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38:904–909
Purcell S, Neale B, Todd-Brown K et al (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81:559–575
Willer CJ, Li Y, Abecasis GR (2010) METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 26:2190–2191
Yang J, Lee SH, Goddard ME, Visscher PM (2011) GCTA: a tool for genome-wide complex trait analysis. Am J Hum Genet 88:76–82
Untergasser A, Cutcutache I, Koressaar T et al (2012) Primer3—new capabilities and interfaces. Nucleic Acids Res 40:e115
Barrett JC (2009) Haploview: visualization and analysis of SNP genotype data. Cold Spring Harb Protoc 2009:pdb.ip71
NCBI Resource Coordinators (2013) Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 41:D8–D20
Segre AV, DIAGRAM Consortium, MAGIC investigators et al (2010) Common inherited variation in mitochondrial genes is not enriched for associations with type 2 diabetes or related glycemic traits. PLoS Genet 6:e1001058
Dickson SP, Wang K, Krantz I, Hakonarson H, Goldstein DB (2010) Rare variants create synthetic genome-wide associations. PLoS Biol 8:e1000294
Anderson CA, Soranzo N, Zeggini E, Barrett JC (2011) Synthetic associations are unlikely to account for many common disease genome-wide association signals. PLoS Biol 9:e1000580
Norio R (2003) Finnish Disease Heritage I: characteristics, causes, background. Hum Genet 112:441–456
Norio R (2003) Finnish Disease Heritage II: population prehistory and genetic roots of Finns. Hum Genet 112:457–469
Kingsmore SF, Suh D, Seldin MF (1994) Genetic mapping of the glycine receptor alpha 3 subunit on mouse chromosome 8. Mamm Genome 5:831–832
Li C, Liu C, Nissim I et al (2013) Regulation of glucagon secretion in normal and diabetic human islets by gamma-hydroxybutyrate and glycine. J Biol Chem 288:3938–3951
den Eynden JV, Ali SS, Horwood N et al (2009) Glycine and glycine receptor signalling in non-neuronal cells. Front Mol Neurosci 2:9
Yin M, Zhong Z, Connor HD et al (2002) Protective effect of glycine on renal injury induced by ischemia-reperfusion in vivo. Am J Physiol Renal Physiol 282:F417–F423
Woroniecka KI, Park AS, Mohtat D, Thomas DB, Pullman JM, Susztak K (2011) Transcriptome analysis of human diabetic kidney disease. Diabetes 60:2354–2369
Schmid H, Boucherot A, Yasuda Y et al (2006) Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes 55:2993–3003
Acknowledgements
We would like to acknowledge M. Parkkonen, A. Sandelin, A.-R. Salonen, T. Soppela and J. Tuomikangas (Folkhälsan Research Center, Helsinki, Finland and Division of Nephrology, Helsinki University Central Hospital, Helsinki, Finland) for their skilful laboratory assistance. We also thank all the patients who participated in the study and gratefully acknowledge all the physicians and nurses at each centre involved in the recruitment of participants (ESM [Table 8]).
Funding
The FinnDiane study was supported by grants from the Folkhälsan Research Foundation, the Wilhelm and Else Stockmann Foundation, Liv och Hälsa Foundation, Helsinki University Central Hospital Research Funds (EVO), the Sigrid Juselius Foundation, the Finnish Cultural Foundation, the Signe and Ane Gyllenberg Foundation, Finska Läkaresällskapet, Academy of Finland (no. 134379), Novo Nordisk Foundation and Tekes. The research was supported by the European Union Seventh Framework Program (FP7/2007–2013) for the Innovative Medicine Initiative under grant agreement no. IMI/115006 (the SUMMIT consortium), the Northern Ireland Research and Development Office and the Northern Ireland Kidney Research Fund.
Duality of interest
P-HG has received lecture honorariums from AbbVie, Boehringer Ingelheim, Cebix, Eli Lilly, Genzyme, Novartis, Novo Nordisk, MSD and Medscape, and research grants from Eli Lilly and Roche. P-HG is also an advisory board member of Boehringer Ingelheim, Eli Lilly and Novartis. The other authors declare that they have no duality of interest associated with this manuscript.
Contribution statement
NS and AJM contributed to the conception and design of the study, analysed and interpreted the data and drafted the article. CF and V-PM contributed to the conception and design of the study and interpretation of the results and critically revised the article. CF also contributed to the acquisition of data. A-MÖ, BH, EA and JC contributed to the analysis and acquisition of the data and critically revised the article. VH, RL, DG, MP, MS, LMT, NT, JW, JT, ML, AM, MLM, DD, ADP, GZ, LG and LT contributed to the acquisition of the phenotype and/or genotype data and reviewed the manuscript critically. APM and KT contributed to the conception and study design and to the data acquisition and revised the article critically.
P-HG designed and supervised the study and reviewed the article critically, and is responsible for the integrity of the work as a whole. All authors approved the final version of the article to be published.
Author information
Authors and Affiliations
Consortia
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
ESM
(PDF 1332 kb)
Rights and permissions
About this article
Cite this article
Sandholm, N., Forsblom, C., Mäkinen, VP. et al. Genome-wide association study of urinary albumin excretion rate in patients with type 1 diabetes. Diabetologia 57, 1143–1153 (2014). https://doi.org/10.1007/s00125-014-3202-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00125-014-3202-3